Régnier, Stephane - In: Health Care Management Science 16 (2013) 4, pp. 300-313
The objective of this article is to estimate the value of ‘follow-on’ or ‘me-too’ drugs from the payer, industry and societal perspectives. Since me-too drugs do not bring additional clinical benefits, they are only valuable to payers if they save costs. An empirical model was...